Delvin Klarvoyant Biogenics Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
as on 13-12-2024
- Paid Up Capital ₹ 1.21 Cr
as on 13-12-2024
- Company Age 13 Year, 11 Months
- Last Filing with ROC 31 Mar 2017
- Open Charges ₹ 1.50 Cr
as on 13-12-2024
- Revenue -30.44%
(FY 2017)
- Profit 52.23%
(FY 2017)
- Ebitda 25.96%
(FY 2017)
- Net Worth -80.18%
(FY 2017)
- Total Assets -15.49%
(FY 2017)
About Delvin Klarvoyant Biogenics
The Corporate was formerly known as Klarvoyant Biogenics Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2017. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 1.21 Cr.
The company currently has active open charges totaling ₹1.50 Cr.
Sebi Pius, Rahul Raj, Deepu Mathew, and One other member serve as directors at the Company.
- CIN/LLPIN
U24100TN2011PTC078875
- Company No.
078875
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jan 2011
- Date of AGM
30 Sep 2017
- Date of Balance Sheet
31 Mar 2017
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Delvin Klarvoyant Biogenics?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sebi Pius  | Director | 19-Jan-2011 | Current |
| Rahul Raj | Director | 12-Nov-2017 | Current |
| Deepu Mathew | Director | 12-Nov-2017 | Current |
| Rajesh Vellattunkara | Director | 12-Nov-2017 | Current |
Financial Performance of Delvin Klarvoyant Biogenics.
Delvin Klarvoyant Biogenics Private Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 30.44% decrease. The company also saw a substantial improvement in profitability, with a 52.23% increase in profit. The company's net worth observed a substantial decline by a decrease of 80.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Delvin Klarvoyant Biogenics?
In 2017, Delvin Klarvoyant Biogenics had a promoter holding of 83.47% and a public holding of 16.53%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 11 Jul 2016 | ₹1.50 Cr | Open |
How Many Employees Work at Delvin Klarvoyant Biogenics?
Delvin Klarvoyant Biogenics has a workforce of 1 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Delvin Klarvoyant Biogenics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Delvin Klarvoyant Biogenics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
